The Triple Threat: TAS-102, Irinotecan, and Bevacizumab Take on Colorectal Cancer

Somewhere between your morning coffee and your lunch break today, about 400 people worldwide heard the words "metastatic colorectal cancer." And for a big chunk of those people, their first round of chemotherapy has already stopped working - which is a bit like discovering your car's brakes failed while going downhill. The search for a reliable Plan B has been one of oncology's most stubborn quests, but a team of researchers just showed up with a promising new map.

Meet the Cast of Characters

Every good story needs a team-up, and this one features three drugs that decided they're stronger together - like a buddy heist film, but the thing being stolen is tumor growth.

Trifluridine/tipiracil (street name: TAS-102, brand name: Lonsurf) is an oral chemo agent that sneaks into cancer cell DNA and wrecks the place from the inside. Think of it as the infiltrator. Irinotecan is the heavy hitter - a topoisomerase inhibitor that essentially tangles up cancer's ability to copy itself, like someone deliberately knotting your earbuds. And bevacizumab (you know it as Avastin) plays the strategist, cutting off the blood supply tumors need to grow. It starves the villain's supply lines.

Individually, each has a decent resume. But researchers at multiple centers across China wondered: what happens when you send all three in at once, earlier in treatment than anyone had tried before?

The Heist Goes Down

In this phase II multicenter trial (NCT06202001), 60 patients with metastatic colorectal cancer that had already shrugged off first-line fluoropyrimidine and oxaliplatin-based chemo were enrolled between October 2023 and August 2024. These patients received biweekly cycles of all three drugs - TAS-102 orally, plus irinotecan and bevacizumab by IV (Yang et al., 2026).

Here's where the plot gets good.

The objective response rate hit 18.3% - including two complete responses, which in the metastatic setting is basically the cancer equivalent of a standing ovation. The disease control rate reached a remarkable 83.3%, meaning five out of every six patients saw their disease at least stabilize. Median progression-free survival came in at 6.6 months, and the real showstopper: median overall survival of 17.3 months.

For context, the landmark SUNLIGHT trial showed that TAS-102 plus bevacizumab alone (without irinotecan) achieved a median overall survival of 10.8 months in the third-line setting (Prager et al., 2023). This new triple combo, used a full line earlier, nearly doubled that number. That's not a marginal improvement - that's a plot twist.

The Subplot Nobody Expected

Buried in the subgroup analysis was a finding that made surgeons sit up a little straighter: patients who'd previously had their primary tumor removed did dramatically better. Their median overall survival was 21.9 months versus 16.2 months for those who hadn't, and PFS was 8.9 versus 5.2 months. The role of primary tumor resection in metastatic disease has been debated for years - this data just handed one side some very compelling ammunition.

The Villain Fights Back (Side Effects)

No heist goes perfectly clean. Nausea showed up in 100% of patients - every single one. Neutropenia hit 86.7%, with nearly half experiencing grade 3 or 4 severity. Febrile neutropenia occurred in 8.3%, and diarrhea in 6.7%. These numbers aren't trivial, but the researchers describe the overall safety profile as "manageable," and no treatment-related deaths were reported. The crew took some hits, but everybody walked out.

What Happens Next

This is a single-arm phase II trial with 60 patients - compelling enough to get everyone's attention, but not yet the kind of evidence that rewrites treatment guidelines. The TABAsCO trial in Italy found similar promise with this triple combination (Rossini et al., 2024), and another Chinese phase II study reported an even higher response rate of 25.8% (Wang et al., 2024). The consistency across studies is the real signal here.

A randomized phase III trial - where this regimen goes head-to-head against standard second-line FOLFIRI plus bevacizumab - is the next chapter this story desperately needs. Until then, 17.3 months of median overall survival in the second-line setting is a number worth paying attention to.

For the 400 people who got that diagnosis today, every month matters. This triple combination might just be buying more of them.

References:

1. Yang W, Zhang J, Liang P, et al. Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study. Signal Transduction and Targeted Therapy. 2026. DOI: 10.1038/s41392-026-02634-3. PMID: 41956997.

2. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine. 2023;388(18):1657-1667. DOI: 10.1056/NEJMoa2214963. PMID: 37133585.

3. Rossini D, Germani MM, Borelli B, et al. TAS-102, irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. British Journal of Cancer. 2024. DOI: 10.1038/s41416-024-02845-x.

4. Wang X, et al. Phase II study of irinotecan, trifluridine/tipiracil (TAS-102) plus bevacizumab as a later-line therapy for patients with metastatic colorectal cancer. 2024. PMID: 39448860. PMC: PMC11589780.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.